Skip to main content
SpringerLink
Log in

The Implantable Insulin Pump

  • Chapter
  • First Online:
Handbook of Diabetes Technology

Abstract

The implantable insulin pump is a treatment option for certain patients with type 1 diabetes when an external insulin pump has failed to stabilize their diabetes despite all appropriate medical and educational efforts. The implanted pump provides an added efficacy for glycemic variability, hypoglycemia, and HbA1c as compared to the external pump’s subcutaneous insulin delivery. This is due to the intraperitoneal insulin administration which is now shown to have long-term and sustainable metabolic benefits. Insulin treatment using an implanted pump is a result of over 30 years of progress in technology and insulin preparation. While its history is made of both successes and problems, recent developments suggest a more optimistic future for disseminating this therapeutic modality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schade DS, Eaton RP, Davis T, et al. The kinetics of peritoneal absorption. Metabolism. 1981;30(2):149–55.

    Article  CAS  Google Scholar 

  2. Schade DS, Eaton RP, Friedman NM, Spencer WJ. Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia. 1980;19(1):35–9.

    Article  CAS  Google Scholar 

  3. Schaepelynck Belicar P, Vague P, Lassmann-Vague V. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps. Diabetes Metab. 2003;29:344–8.

    Article  CAS  Google Scholar 

  4. Oskarsson PR, Lins PE, Backman L, Adamson UC. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycemia in type 1 diabetic patients. Diabetes Metab. 2000;26:118–24.

    CAS  PubMed  Google Scholar 

  5. Broussolle C, Jeandidier N, Hanaire-Broutin H, for the Evadiac Study Group. French multicenter experience with implantable insulin pumps. Lancet. 1994;343:514–5.

    Article  CAS  Google Scholar 

  6. Hanaire-Broutin H, Broussolle C, Jeandidier N, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: a multicenter study. Diabetes Care. 1995;18:388–92.

    Article  CAS  Google Scholar 

  7. Jeandidier N, Selam JL, Renard E, et al. Decreased severe hypoglycaemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Diabetes Care. 1996;19:780.

    Article  CAS  Google Scholar 

  8. Catargi B, Meyer L, Melki V, Renard E, Jeandidier N, for the EVADIAC Study Group. Comparison of blood glucose stability and HbA1c between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabete Metab. 2002;28:133–7.

    CAS  PubMed  Google Scholar 

  9. Logtenberg SJ, Kleefstra N, Houweling ST, et al. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes. A randomized controlled trial. Diabetes Care. 2009;32(8):1372–7.

    Article  CAS  Google Scholar 

  10. Schaepelynck P, Renard E, Jeandidier N, et al. A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. Diabetes Technol Ther. 2011;13(6):657–60.

    Article  Google Scholar 

  11. Van Dijk PR, Logtenberg SJ, Groenier KH, Gans RO, Kleefstra N, Bilo HJ. Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post trial follow-up. BMC Endocr Disord. 2014;14:30.

    Article  Google Scholar 

  12. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-1 and IGF-binding protein-3 in IDDM. Diabetologia. 1996;39:1498–504.

    Article  CAS  Google Scholar 

  13. Hedman CA, Frystyk J, Lindström T, Oskarsson P, Arnqvist HJ. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-1 bioactivity than subcutaneous insulin infusion. Clin Endocrinol. 2014;81:58–62.

    Article  CAS  Google Scholar 

  14. Dal S, Jeandidier N, Schaschkow A, et al. Portal or subcutaneous insulin infusion: efficacy and impact on liver inflammation. Fundam Clin Pharmacol. 2015;29:48–98.

    Article  Google Scholar 

  15. Buchwald H, Barbosa J, Varco RL, et al. Treatment of a type II diabetic by a totally implantable insulin infusion device. Lancet. 1981;1(8232):1233–5.

    Article  CAS  Google Scholar 

  16. Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. 1989;321(9):574–9.

    Article  CAS  Google Scholar 

  17. Grau U, Saudek CD. Stable insulin preparation for implanted insulin pumps. Laboratory and animal trials. Diabetes. 1987;36:1453–9.

    Article  CAS  Google Scholar 

  18. Renard E, Schaepelynck P, on behalf of the EVADIAC Group. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab. 2007;33(2):1 58–66.

    Article  CAS  Google Scholar 

  19. Schaepelynck P, Riveline JP, Renard E, et al. Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes. Diabetes Technol Ther. 2014;16(9):582–9.

    Article  CAS  Google Scholar 

  20. Spaan N, Teplova A, Stam G, Spaan J, Lucas C. Systematic review: continuous intraperitoneal insulin infusion with implantable insulin pumps for diabetes mellitus. Acta Diabetol. 2014;51:339–51.

    Article  CAS  Google Scholar 

  21. Haardt MJ, Selam JL, Slama G, et al. A cost-benefit comparison of intensive management with implantable pumps versus multiple subcutaneous injections in patients with type 1 diabetes. Diabetes Care. 1994;17(8):847–51.

    Article  CAS  Google Scholar 

  22. Selam JL, Raccah D, Jeandidier N, Lozano JL, Waxman K, Charles MA. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type 1 diabetic patients. Diabetes Care. 1992;15(1):53–8.

    Article  CAS  Google Scholar 

  23. Van Dijk PR, Groenier KH, DeVries JH, et al. Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability. Diabetes Technol Ther. 2015;17(6):379–84.

    Article  Google Scholar 

  24. DeVries JH, Eskes SA, Snoek FJ. Continuous intraperitoneal insulin infusion in patients with ‘brittle’ diabetes: favourable effects on glycaemic control and hospital stay. Diabet Med. 2002;19(6):496–501.

    Article  CAS  Google Scholar 

  25. Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Gans RO, Bilo HJ. Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2010;33(6):1169–72.

    Article  Google Scholar 

  26. Olsen CL, Chan E, Turner DS, et al. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care. 1994;17(3):169–76.

    Article  CAS  Google Scholar 

  27. Jeandidier N, Boivin S, Sapin R, et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia. 1995;38(5):577–84.

    Article  CAS  Google Scholar 

  28. Lassmann-Vague V, Belicar P, Raccah D, Vialettes B, Sodoyez JC, Vague P. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences. Diabetes Care. 1995;18(4):498–503.

    Article  CAS  Google Scholar 

  29. Spaan N, Teplova A, Renard E, Spaan J. Implantable insulin pumps: an effective option with restricted dissemination. Lancet Diabetes Endocrinol. 2014;2(5):358–60.

    Article  Google Scholar 

  30. Dassau E, Renard E, Place J, et al. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study. Diabetes Obes Metab. 2017;19(12):1698–705.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetology, Marseille University Hospital, Marseille, France

    Pauline Schaepelynck

Authors
  1. Pauline Schaepelynck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pauline Schaepelynck .

Editor information

Editors and Affiliations

  1. Department of Endocrinology, Centre Hospitalier Universitaire de Caen, CAEN CEDEX 9, France

    Yves Reznik

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schaepelynck, P. (2019). The Implantable Insulin Pump. In: Reznik, Y. (eds) Handbook of Diabetes Technology. Springer, Cham. https://doi.org/10.1007/978-3-319-98119-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98119-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98118-5

  • Online ISBN: 978-3-319-98119-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation